Targeting endoglin, an auxiliary transforming growth factor β coreceptor, to prevent fibrosis and heart failure

Circulation

Volumn 125, Issue 22, 2012, Pages 2689-2691

  Benjamin, Ivor J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Editorials; Endoglin protein, mouse; Fibrosis; Heart failure

Indexed keywords

ENDOGLIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; STRUCTURAL PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3;

ACUTE HEART INFARCTION; DIASTOLIC DYSFUNCTION; EDITORIAL; EXTRACELLULAR MATRIX; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; HEART FAILURE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MYOCARDIUM; RECEPTORS, CELL SURFACE;

EID: 84861863431     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.108282     Document Type: Editorial

References (18)

1. Bristow MR. Treatment of chronic heart failure with-adrenergic receptor antagonists: A convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011;109:1176-1194.
2. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S. Beta 1-and beta 2-adrenergicreceptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986; 59:297-309. (Pubitemid 17178124)
3. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-by anti-TGF-antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996;45:522-530.
4. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl G, Bauersachs J. Transforming growth factor-inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol. 2008;103:485-492.
5. Kapur NK, Wilson S, Yunis AA, Qiao X, Mackey E, Parurchuri A, Baker C, Aronovitz MJ, Karumanchi SA, Letarte M, Kass DA, Mendelson ME, Karas RH. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation. 2012;125:2728-2738.
6. Gougos A, Letarte M. Primary structure of endoglin, an rgd-containing glycoprotein of human endothelial cells. J Biol Chem. 1990;265: 8361-8364.
7. Lopez-Novoa JM, Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2010;299: H959-H974.
8. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333:918-924.
9. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J. Endoglin, a TGF-binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8:345-351.
10. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP. Defective angiogenesis in mice lacking endoglin. Science. 1999;284:1534-1537.
11. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest. 1999;104:1343-1351.
12. Bourdeau A, Faughnan ME, McDonald ML, Paterson AD, Wanless IR, Letarte M. Potential role of modifier genes influencing transforming growth factor-1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol. 2001;158:2011-2020.
13. Cruz-Gonzalez I, Pabon P, Rodriguez-Barbero A, Martin-Moreiras J, Pericacho M, Sanchez PL, Ramirez V, Sanchez-Ledesma M, Martin-Herrero F, Jimenez-Candil J, Maree AO, Sanchez-Rodriguez A, Martin-Luengo C, Lopez-Novoa JM. Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction. J Cell Mol Med. 2008;12:955-961. (Pubitemid 351718073)
14. Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, Recio-Rodriguez JI, Sanchez-Rodriguez A, Lopez-Novoa JM, Martinez-Salgado C. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med. 2010;8:86.
15. Toporsian M, Jerkic M, Zhou YQ, Kabir MG, Yu LX, McIntyre BA, Davis A, Wang YJ, Stewart DJ, Belik J, Husain M, Henkelman M, Letarte M. Spontaneous adult-onset pulmonary arterial hypertension attributable to increased endothelial oxidative stress in a murine model of hereditary hemorrhagic telangiectasia. Arterioscler Thromb Vasc Biol. 2010;30:509-517.
16. Akoum N, Daccarett M, McGann C, Segerson N, Vergara G, Kuppahally S, Badger T, Burgon N, Haslam T, Kholmovski E, Macleod R, Marrouche N. Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach. J Cardiovasc Electrophysiol. 2011;22:16-22.
17. Shyu KG, Wang BW, Chen WJ, Kuan P, Hung CR. Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-1 in cultured cardiac fibroblasts. Eur J Heart Fail. 2010;12:219-226.
18. Burke JP, Watson RW, Mulsow JJ, Docherty NG, Coffey JC, O'Connell PR. Endoglin negatively regulates transforming growth factor-1-induced profibrotic responses in intestinal fibroblasts. Br J Surg. 2010;97:892-901.